CONTACT LORUS THERAPEUTICS INC. CANADIAN MEDIA: Corporate Communications MANSFIELD COMMUNICATIONS INC. Grace Tse Hugh Mansfield Tel: (416) 798-1200, ext.380 Tel: (416) 599-0024 Email: ir@lorusthera.com Email: hmansfield@mcipr.com TSE: LOR OTC BB: LORFF LORUS THERAPEUTICS REPORTS THIRD QUARTER RESULTS TORONTO, CANADA - APRIL 11, 2003 - Lorus Therapeutics Inc. ("Lorus") today announced third quarter financial results for the quarter ended February 28, 2003. All figures, unless otherwise specified, are in Canadian dollars. DECEMBER 1, 2002 TO DATE HIGHLIGHTS o A milestone was achieved in the quarter, as the Company recorded its first ever revenue in the company's history from the sale of Virulizin(R) in Mexico. o The Company expanded the ongoing phase II clinical trial of GTI-2040 in renal cell carcinoma from one site to six major oncology centers in the U.S. o The U.S. National Cancer Institution (NCI) approved six protocols in a multiple phase II clinical trial program with GTI-2040 including breast cancer, colon cancer, non-small cell lung cancer, acute myeloid leukemia, prostate cancer, and a range of solid tumors. o GTI-2040 was awarded Orphan Drug Status by the U.S. Food and Drug Administration (FDA) for the treatment of advanced renal cell carcinoma. This status allows the FDA to help facilitate the drug's development process by providing financial incentives and granting seven years of market exclusivity in the U.S. independent of patent protection upon approval of the drug in the U.S. o The United States Patent and Trademark Office (USPTO) allowed Lorus another patent to protect the company's lead anticancer drug Virulizin(R) as it relates to immunomodulating compositions for the treatment of immune system disorders. o The Mexican Patent Office allowed Lorus a patent to protect the immunomodulator composition, process for preparation and use of Virulizin(R) for the treatment of cancer. The allowance is critically important to Lorus' strategic plan for maximizing the value of Virulizin(R) in its first commercial marketplace. o Appointed Dr. Robert Capizzi who is a seasoned oncologist to the board of directors and retained the services of Mr. Bruce Rowlands, who is an experienced professional with in-depth knowledge of public market and investor relations, as its Senior Advisor with responsibilities in the area of Investor Relations. "We are pressing full speed ahead to enhance shareholder value in this quarter. We expanded our clinical trials, continuously enhanced our patent portfolios and strengthened the board and management team," said Dr. Jim A. Wright, chief executive officer, Lorus. "Support from the NCI through the sponsorship of six additional GTI-2040 clinical trials provides scientific and clinical validation of our antisense drug development program in the U.S., the largest cancer drug market in the world." Net loss for the third quarter ended February 28, 2003 totaled $3,802,000 ($0.026 per share) compared to a loss of $3,028,000 ($0.021 per share) for the same quarter last year. The loss was $11,847,000 ($0.082 per share) for the first nine months of fiscal 2003 compared to $9,767,000 ($0.068 per share) for the comparable period last year. The increase in net loss relates primarily to higher level of activities with the Virulizin(R) Phase III clinical trial and expanded GTI-2040 phase II trials and lower interest income, partially offset by lower administrative costs from cost conservation efforts and the ceasing of amortization of goodwill in accordance with the adoption of a new accounting pronouncement effective June 1, 2002. On a comparable basis, the loss for the three months and nine months ended February 28, 2002 would have been $2,664,000 ($0.019 per share) and $8,676,000 ($0.061 per share) respectively after adjustment to remove the amortization of goodwill. Research and development expenses for the third quarter of fiscal 2003 increased to $2,876,000 compared to $1,872,000 for the same quarter last year. For the nine months ended February 28, 2003, research and development expenses increased to $9,246,000 compared to $6,107,000 for the same period last year. Cost increases in fiscal 2003 can be attributed primarily to higher clinical trial costs for the ongoing pivotal Phase III trial of Virulizin(R) for the treatment of advanced pancreatic cancer and an expanded GTI-2040 phase II trial in patients with renal cell carcinoma. General and administrative expenses for the third quarter of fiscal 2003 decreased to $960,000 compared to $1,209,000 for the same quarter last year. For the nine months ended February 28, 2003, general and administrative expenses decreased to $3,060,000 compared to $3,854,000 for the same period last year. The decrease in both periods was due mainly to lower use of external advisory services, and ongoing cost containment. Depreciation and amortization for the third quarter of fiscal 2003 decreased to $224,000 from $458,000 for the same quarter last year. For the nine months ended February 28, 2003, depreciation and amortization expenses decreased to $483,000 from $1,480,000 during the same period last year. In both periods, the decrease was due mainly to the adoption of the new CICA accounting pronouncement for goodwill and other intangible assets whereby the Company ceased amortizing goodwill on June 1, 2002. Interest income for the third quarter of fiscal 2003 decreased to $258,000 from $511,000 for the same quarter last year. For the nine months ended February 28, 2003, interest income decreased to $942,000 from $1,674,000 for the same period last year. These decreases can be attributed primarily to lower cash and short-term investments balances in fiscal 2003. At February 28, 2003 Lorus had cash and cash equivalents and short-term investments totaling $27.7 million compared to $37.8 million at May 31, 2002. Working capital was $24.3 million at February 28, 2003 compared to $35.6 million at May 31, 2002. CONSOLIDATED STATEMENTS OF LOSS (UNAUDITED) FOR THE QUARTERS ENDED FEBRUARY 28, 2003 AND 2002